Cocrystal Pharma Initiates CDI-988 Norovirus Challenge Study
Cocrystal Pharma announces the first subjects have been dosed in a Phase 1b norovirus challenge study to evaluate CDI-988 as both a preventive and treatment for norovirus infections. This cohort is to assess the infectivity rate of the challenge inoculum, GII.2. CDI-988 is a direct-acting, oral antiviral designed to inhibit a highly conserved region of the viral 3CL protease present in all known norovirus strains, including GII.2, GII.4 and recently re-emerging GII.17 variants. It is the first oral antiviral drug candidate developed for norovirus acute gastroenteritis.
Trade with 70% Backtested Accuracy
Analyst Views on COCP
About COCP
About the author
Cocrystal Pharma Reports FY 2025 Earnings Results
- Earnings Highlights: Cocrystal Pharma reported a FY 2025 GAAP EPS of -$0.78, beating expectations by $0.02, indicating a slight improvement in financial performance despite still being in a loss position.
- Cash Position: As of December 31, 2025, Cocrystal's unrestricted cash stood at $7.7 million, down from $9.9 million in 2024, reflecting pressure on the company's financial management that could impact future operational capabilities.
- Operating Cash Usage: The net cash used in operating activities for 2025 was $8.2 million, significantly reduced from $16.5 million in 2024, suggesting that the company has made progress in cost control and resource allocation, potentially laying the groundwork for future financial stability.
- Market Attention: Cocrystal Pharma's financial data has garnered market attention, particularly under Seeking Alpha's Quant Rating, with investors showing cautious optimism regarding the company's future profitability and cash flow management.
Cocrystal Receives IRB Approval to Initiate CDI-988 Clinical Trial, Enrollment Expected Q1 2026
- Clinical Trial Approval: Cocrystal Pharma has received approval from the Emory University Institutional Review Board to initiate a Phase 1b human challenge study for CDI-988, with enrollment expected to begin in Q1 2026, aiming to evaluate its efficacy in preventing and treating norovirus infections.
- Innovative Drug Development: CDI-988 is the first oral broad-spectrum antiviral drug specifically designed to inhibit the 3CL protease of all noroviruses, potentially revolutionizing management in high-risk environments such as hospitals and nursing homes.
- Global Health Impact: With norovirus causing approximately 700 million infections annually, Cocrystal's research addresses this significant global health challenge, which could substantially reduce cases of acute gastroenteritis and associated societal costs.
- Technological Platform Advantage: Leveraging its proprietary structure-based drug discovery platform, Cocrystal aims to rapidly develop novel antiviral agents, and the success of CDI-988 will further solidify its leadership position in the antiviral space, driving future growth for the company.
Cocrystal Pharma to Present Clinical Progress at NobleCon 21
- Conference Presentation: Cocrystal Pharma's CFO and co-CEO James Martin will present a company overview and clinical progress update at NobleCon 21 on December 3, 2025, showcasing the latest advancements in antiviral treatments.
- Investor Participation: The conference invites interested investors and guests to attend at a discounted rate, aiming to increase visibility and engagement within the small and micro-cap market.
- Webcast Availability: A video of Cocrystal's presentation will be available on December 4 and archived for 90 days on the company's website, ensuring that investors unable to attend live can access critical information.
- Company Background: Cocrystal Pharma is a clinical-stage biotechnology firm focused on developing innovative antiviral treatments for diseases such as influenza, viral gastroenteritis, COVID, and hepatitis, leveraging unique structure-based technologies and Nobel Prize-winning expertise to create first-in-class antiviral drugs.
Cocrystal Pharma to Showcase at Noble Capital Markets Virtual Equity Conference for Emerging Growth Companies
Cocrystal Pharma Presentation: Cocrystal Pharma's CFO and co-CEO, James Martin, will present a company overview at the Noble Capital Markets Emerging Growth Virtual Equity Conference on October 9, 2025, followed by a Q&A session.
Company Background: Cocrystal Pharma is a clinical-stage biotechnology firm focused on developing innovative antiviral treatments for diseases like influenza and COVID, utilizing unique technologies and expertise.
Cocrystal Pharma reveals direct offering of up to $13 million.
Stock Offering Details: Cocrystal Pharma has announced a registered direct offering of 2.76 million shares at $1.70 per share, alongside a private placement of unregistered warrants for up to 5.53 million shares at an exercise price of $1.50.
Financial Projections: The company expects to raise approximately $4.7 million from the offering, with potential additional proceeds of about $8.3 million if the warrants are fully exercised.
Cocrystal Pharma's Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain
CC-42344 Antiviral Efficacy: Cocrystal Pharma's CC-42344 has demonstrated strong antiviral activity against the highly pathogenic H5N1 avian influenza strain, being approximately 1,000-fold more potent than Tamiflu, with favorable safety and tolerability in initial studies.
Concerns Over Avian Influenza Spread: The emergence of H5N1 in dairy cows has raised concerns about potential human-to-human transmission, as evidenced by confirmed human cases linked to exposure, highlighting the need for effective treatments like CC-42344.
Cocrystal Pharma Reports FY 2025 Earnings Results
- Earnings Highlights: Cocrystal Pharma reported a FY 2025 GAAP EPS of -$0.78, beating expectations by $0.02, indicating a slight improvement in financial performance despite still being in a loss position.
- Cash Position: As of December 31, 2025, Cocrystal's unrestricted cash stood at $7.7 million, down from $9.9 million in 2024, reflecting pressure on the company's financial management that could impact future operational capabilities.
- Operating Cash Usage: The net cash used in operating activities for 2025 was $8.2 million, significantly reduced from $16.5 million in 2024, suggesting that the company has made progress in cost control and resource allocation, potentially laying the groundwork for future financial stability.
- Market Attention: Cocrystal Pharma's financial data has garnered market attention, particularly under Seeking Alpha's Quant Rating, with investors showing cautious optimism regarding the company's future profitability and cash flow management.
Cocrystal Receives IRB Approval to Initiate CDI-988 Clinical Trial, Enrollment Expected Q1 2026
- Clinical Trial Approval: Cocrystal Pharma has received approval from the Emory University Institutional Review Board to initiate a Phase 1b human challenge study for CDI-988, with enrollment expected to begin in Q1 2026, aiming to evaluate its efficacy in preventing and treating norovirus infections.
- Innovative Drug Development: CDI-988 is the first oral broad-spectrum antiviral drug specifically designed to inhibit the 3CL protease of all noroviruses, potentially revolutionizing management in high-risk environments such as hospitals and nursing homes.
- Global Health Impact: With norovirus causing approximately 700 million infections annually, Cocrystal's research addresses this significant global health challenge, which could substantially reduce cases of acute gastroenteritis and associated societal costs.
- Technological Platform Advantage: Leveraging its proprietary structure-based drug discovery platform, Cocrystal aims to rapidly develop novel antiviral agents, and the success of CDI-988 will further solidify its leadership position in the antiviral space, driving future growth for the company.
Cocrystal Pharma to Present Clinical Progress at NobleCon 21
- Conference Presentation: Cocrystal Pharma's CFO and co-CEO James Martin will present a company overview and clinical progress update at NobleCon 21 on December 3, 2025, showcasing the latest advancements in antiviral treatments.
- Investor Participation: The conference invites interested investors and guests to attend at a discounted rate, aiming to increase visibility and engagement within the small and micro-cap market.
- Webcast Availability: A video of Cocrystal's presentation will be available on December 4 and archived for 90 days on the company's website, ensuring that investors unable to attend live can access critical information.
- Company Background: Cocrystal Pharma is a clinical-stage biotechnology firm focused on developing innovative antiviral treatments for diseases such as influenza, viral gastroenteritis, COVID, and hepatitis, leveraging unique structure-based technologies and Nobel Prize-winning expertise to create first-in-class antiviral drugs.
Cocrystal Pharma to Showcase at Noble Capital Markets Virtual Equity Conference for Emerging Growth Companies
Cocrystal Pharma Presentation: Cocrystal Pharma's CFO and co-CEO, James Martin, will present a company overview at the Noble Capital Markets Emerging Growth Virtual Equity Conference on October 9, 2025, followed by a Q&A session.
Company Background: Cocrystal Pharma is a clinical-stage biotechnology firm focused on developing innovative antiviral treatments for diseases like influenza and COVID, utilizing unique technologies and expertise.
Cocrystal Pharma reveals direct offering of up to $13 million.
Stock Offering Details: Cocrystal Pharma has announced a registered direct offering of 2.76 million shares at $1.70 per share, alongside a private placement of unregistered warrants for up to 5.53 million shares at an exercise price of $1.50.
Financial Projections: The company expects to raise approximately $4.7 million from the offering, with potential additional proceeds of about $8.3 million if the warrants are fully exercised.
Cocrystal Pharma's Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain
CC-42344 Antiviral Efficacy: Cocrystal Pharma's CC-42344 has demonstrated strong antiviral activity against the highly pathogenic H5N1 avian influenza strain, being approximately 1,000-fold more potent than Tamiflu, with favorable safety and tolerability in initial studies.
Concerns Over Avian Influenza Spread: The emergence of H5N1 in dairy cows has raised concerns about potential human-to-human transmission, as evidenced by confirmed human cases linked to exposure, highlighting the need for effective treatments like CC-42344.
